Stocktoria
Samsung Biologics Co.,Ltd. 207940.KS
KR · Korea Exchange · XKRX · stock · Healthcare · website
Samsung Biologics Co.,Ltd. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | ₩4.56T | ₩3.50T | ₩3.69T | ₩3.00T |
| Gross profit | ₩2.52T | ₩1.71T | ₩1.80T | ₩1.47T |
| R&D expense | ₩37.2B | ₩36.7B | ₩81.6B | ₩45.9B |
| SG&A expense | ₩169.6B | ₩193.1B | ₩303.5B | ₩209.5B |
| Operating income | ₩2.07T | ₩1.32T | ₩1.11T | ₩983.6B |
| Interest expense | ₩29.2B | ₩34.1B | ₩81.6B | ₩64.1B |
| Income tax | ₩504.3B | ₩344.6B | ₩262.3B | ₩211.0B |
| Net income | ₩1.78T | ₩1.08T | ₩857.7B | ₩798.1B |
| EPS (diluted) | ₩26628.00 | ₩15221.00 | ₩12051.00 | ₩11432.00 |
| Operating cash flow | ₩2.25T | ₩1.66T | ₩1.67T | ₩953.0B |
| Free cash flow | ₩772.7B | ₩281.7B | ₩560.9B | -₩56.2B |
| Cash & equivalents | ₩148.9B | ₩391.2B | ₩367.9B | ₩890.8B |
| Inventory | ₩2.13T | ₩2.82T | ₩2.64T | ₩2.38T |
| Goodwill | — | ₩1.68T | ₩1.68T | ₩1.68T |
| Total assets | ₩11.06T | ₩17.34T | ₩16.05T | ₩16.58T |
| Total debt | ₩927.1B | ₩1.49T | ₩1.91T | ₩2.51T |
| Total liabilities | ₩3.61T | ₩6.43T | ₩6.22T | ₩7.60T |
| Shareholders' equity | ₩7.45T | ₩10.90T | ₩9.83T | ₩8.98T |
| Share buybacks | ₩92.0B | — | — | — |
Growth · year-over-year · Revenue CAGR 14.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +30.3% | -5.3% | +23.1% | — |
| Net income growth | +64.7% | +26.3% | +7.5% | — |
| EPS growth | +74.9% | +26.3% | +5.4% | — |
| Free cash flow growth | +174.3% | -49.8% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · KR · as of 2025-12-31. Figures in KRW. Facts plus Stocktoria's own computed scores — not investment advice.